98343323

Information

• Trademark
• 98343323

• Source

• Serial Number

  98343323

• International Classifications

  • 35 - Advertising
  • 42 - Scientific and technological services and research and design relating thereto
  • 44 - Medical services

• Filing Date

  January 05, 2024
  a year ago

• Transaction Date

  March 19, 2025
  4 months ago

• Status Date

  October 22, 2024
  9 months ago

• Location Date

  October 22, 2024
  9 months ago

• Status Code

  692

• Current Location

  PUBLICATION AND ISSUE SECTION

  Employee Name

  SULLIVAN,JOHN C

• Attorney Docket Number

  767095.00010

  Attorney Name

  Anna Kurian Shaw

  Law Office Assigned Location Code

  M50

• Owners

  • Tevogen Bio Inc.

Case File Statements

• DM0000: The mark consists of a stylized lymphocyte cell created by an irregular circular shape with a smaller irregular circular shape in the middle with a variety of printed electronic circuits in between.
• CC0000: Color is not claimed as a feature of the mark.
• GS0351: Promoting collaboration in the field of biotechnology to achieve innovation through increased usage of artificial intelligence (AI) technology; promoting the benefits of the use of artificial intelligence (AI) technology in the field of biotechnology to expedite drug development, optimize laboratory processes, unravel complex biological data, and improve patient outcomes; promotion and advocacy services, namely promoting the benefits of the advancement of biomedical, biotechnological, and immunological research and the curing of various diseases utilizing artificial intelligence (AI) technology, by means of public advocacy; promotion and advocacy services, namely, promoting the benefits of increasing the affordability of and increased access to medical services and the treatment of various diseases, as well as overall patient-centric medical services, utilizing artificial intelligence (AI) technology, by means of public advocacy; promotion and advocacy services, namely promoting the benefit of the treatment of various diseases using T cell therapies and artificial intelligence (AI) technology, by means of public advocacy; promoting collaboration within the scientific, research and medical provider communities to achieve advances in the fields of biotechnology, biomedicine, immunology, immunotherapies, and T-cell therapies utilizing artificial intelligence (AI) technology; business operations consulting in the fields of biotechnology and life sciences; business operations consulting in the fields of biotechnology and life sciences to increase business processes automation and increase the efficiency of business operations procedures; database management in the fields of biotechnology and life sciences; creation being compilation and systemization of information into databases and management of databases in the fields of biotechnology and life sciences; compilation of information into computer databases in the fields of biotechnology and life sciences; systematization of data through a medical device network for medical research purposes; business data analysis in the fields of biotechnology and life sciences; business consulting and management in the field of clinical trials, namely, management and compilation of computerized databases in the field of clinical trials for business purposes; business feasibility study planning, namely, for clinical trials; business study data interpretation, namely, for clinical trials; business consulting and management in the field of clinical trials, namely, clinical data and regulatory submission management on behalf of medical, biopharmaceutical and biotechnology companies to assist them with clinical research, clinical trials and applications for drug approval
• GS0441: Providing a website featuring news and information concerning biotechnology, biomedicine, immunology, immunotherapies, and T-cell therapies that utilize artificial intelligence (AI) technology; providing news and information concerning the prevention and treatment of oncological diseases, autoimmune diseases, neurological diseases, viral infections, and COVID-19 using artificial intelligence (AI) enabled technology; providing information concerning use of T cells and other lymphocytes for the prevention and treatment of various diseases, as enhanced by artificial intelligence (AI) technology
• GS0421: Providing a website featuring news and information concerning biomedical, biotechnological, and immunological research that utilizes artificial intelligence (AI) technology; providing news and information concerning biomedical, biotechnological, and immunological research that utilizes artificial intelligence (AI) technology; providing information concerning biomedical research into the efficacy of T cells and other lymphocytes for the prevention and treatment of various diseases, as enhanced by artificial intelligence (AI) technology; providing medical and scientific research information in the fields of T cell therapies, biologics, pharmaceuticals, and clinical trials that utilize artificial intelligence (AI) technology; providing a website featuring temporary access to non-downloadable computer software for expediting drug development, optimizing laboratory processes, and unravelling complex biological data; providing a website featuring temporary access to non-downloadable computer software for human leukocyte antigen (HLA) specificity mapping; providing a website featuring temporary access to non-downloadable computer software for protein sequencing and genome matching; hosting of non-downloadable computer software for clinical trial and patient information database management; providing online, non-downloadable computer software for machine learning and training of artificial intelligence models in the fields of biomedical, biotechnological, and immunological research; analysis of data from databases in the fields of biotechnology and life sciences; collection of data through a medical device network for medical research purposes; providing an internet-based database for business purposes designed to facilitate complex statistical techniques, programming technologies and validation procedures to support clinical trials containing clinical trial data

Case File Event Statements

• 1/5/2024 - a year ago

  1 - NEW APPLICATION ENTERED Type: NWAP

• 4/23/2024 - a year ago

  3 - NOTICE OF DESIGN SEARCH CODE E-MAILED Type: MDSC

• 4/23/2024 - a year ago

  2 - NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Type: NWOS

• 8/1/2024 - a year ago

  4 - ASSIGNED TO EXAMINER Type: DOCK

• 8/6/2024 - a year ago

  6 - NON-FINAL ACTION E-MAILED Type: GNRT

• 8/6/2024 - a year ago

  7 - NOTIFICATION OF NON-FINAL ACTION E-MAILED Type: GNRN

• 8/6/2024 - a year ago

  5 - NON-FINAL ACTION WRITTEN Type: CNRT

• 9/9/2024 - 11 months ago

  9 - CORRESPONDENCE RECEIVED IN LAW OFFICE Type: CRFA

• 9/9/2024 - 11 months ago

  8 - TEAS RESPONSE TO OFFICE ACTION RECEIVED Type: TROA

• 9/10/2024 - 11 months ago

  10 - TEAS/EMAIL CORRESPONDENCE ENTERED Type: TEME

• 10/1/2024 - 10 months ago

  15 - APPROVED FOR PUB - PRINCIPAL REGISTER Type: CNSA

• 10/1/2024 - 10 months ago

  11 - EXAMINERS AMENDMENT -WRITTEN Type: CNEA

• 10/1/2024 - 10 months ago

  14 - EXAMINER'S AMENDMENT ENTERED Type: XAEC

• 10/1/2024 - 10 months ago

  13 - NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED Type: GNEN

• 10/1/2024 - 10 months ago

  12 - EXAMINERS AMENDMENT E-MAILED Type: GNEA

• 10/22/2024 - 9 months ago

  16 - WITHDRAWN FROM PUB - OG REVIEW QUERY Type: PBCR

• 3/13/2025 - 4 months ago

  19 - TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED Type: REAP

• 3/13/2025 - 4 months ago

  17 - TEAS CHANGE OF OWNER ADDRESS RECEIVED Type: COAR

• 3/13/2025 - 4 months ago

  20 - ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED Type: ARAA

• 3/13/2025 - 4 months ago

  21 - TEAS CHANGE OF CORRESPONDENCE RECEIVED Type: TCCA

• 3/13/2025 - 4 months ago

  18 - APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED Type: CHAN